Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products… This content is
This is mainly useful for cardiovascular service planning, prevention messaging, and treatment-pathway discussions.
ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.